ClinicalTrials.gg
Active, not recruitingNCT06620003Updated Sep 10, 2026

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

A Phase 2 interventional study of cAd3-Marburg Vaccine and Placebo in Marburg Virus Disease, sponsored by Albert B. Sabin Vaccine Institute. Active, not recruiting at 7 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Albert B. Sabin Vaccine Institute · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

Read the detailed description

This is a multi-center, double-blinded, placebo-controlled, Phase 2 study to evaluate safety, tolerability, and immunogenicity of a single dose of cAd3-Marburg Vaccine in healthy adults 18 to 70 years of age, in a US-based population. The study will enroll 200 eligible participants randomized 4:1 to receive the cAd3-Marburg Vaccine at 1.0 × 10\^11 PU/dose or placebo (normal saline; 0.9% sodium chloride (NaCl) solution for injection) at Day 1, intramuscularly, in deltoid muscle. Participants will be screened for eligibility up to 28 days before enrollment. Safety data will be periodically reviewed by an independent DSMB. Safety and immunogenicity will be assessed at Days 1, 8, 15, 29, 85, 169, and will conclude at the end of study visit on Day 366. PBMCs will be collected from a subset of 40 subjects on days 1, 15, 29, 169 and will conclude at the end of study visit on Day366 to access cellular immunity. All participants will also be contacted telephonically on Days 4 and 42 (unless a clinic visit is medically indicated, or participant does not have a phone contact) for safety follow-up.

02

Conditions studied

  • Marburg Virus Disease

Keywords

  • Marburg Virus
  • Marburg Vaccine
  • cAd3-Marburg vaccine
03

In context

Lead sponsor

Albert B. Sabin Vaccine Institute is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to complete and provide prior to any trial procedure including optional consent for retention of blood samples for potential future testing and assay development. As part of the informed consent process, the participant must complete a Test of Understanding (ToU) about the study and answer at least 90% of the questions correctly at least once in three attempts.
  2. Male or non-pregnant female 18 to 70 (inclusive) years of age at time of consent;
  3. Is capable of understanding and agrees to comply with planned trial procedures and to be available for all clinic follow-up for all planned trial visits;
  4. Able to provide proof of identity to the satisfaction of the trial clinician completing the enrollment process; has a means to be contacted and to contact the investigator during the trial;
  5. Agree not to receive any vaccine within 3 months of trial vaccination (prior and after) trial;
  6. Agree not to donate bone marrow, blood, or blood products until 3 months after the trial vaccination;
  7. In good general health without medical conditions, based on medical history, physical examination, vital signs, and clinical laboratory results as deemed acceptable by PI;
  8. Clinical laboratory results within 28 days prior to vaccination within the testing laboratory reference ranges (or deemed not clinically significant by the PI) for the following parameters: White blood cells (WBC), Complete blood count (CBC), Red blood cells (RBC), (HGB), total lymphocyte count, coagulation tests to include in terms of INR, fibrinogen, protein C, d-dimer, and chemistry tests to include (ALT), aspartate aminotransferase (AST), and serum creatinine. A laboratory result that is outside the reference range and is deemed not clinically significant by the PI will not exclude the participant;
  9. Has a (BMI) > 17 and ≤ 37 at screening.

    Female participant specific criteria:

  10. Negative pregnancy serum test at screening, and negative urine pregnancy test before vaccination AND:
  11. Use of oral, implantable, transdermal or injectable for 21 days prior to vaccination and for at least 24 weeks after vaccination, UNLESS the female participant fulfills one of the following criteria:

    1. At least 1 year .
    2. Surgically sterile.
    3. Use of another reliable form of contraception must be approved by the Investigator (e.g., double barrier method, intrauterine device, contraceptive patches).

    Male participants must agree:

  12. Not to father a child or donate sperm for at least 24 weeks after vaccination;
  13. To use an effective means of birth control from at least 21 days prior to vaccination and for at least 24 weeks after vaccination if assessed to be of .

Exclusion criteria

Exclusion Criteria:

  1. Participant is female and is breastfeeding or plans to become pregnant or breastfeed from trial vaccination through 24 weeks post-vaccination
  2. Has any medical disease or condition that, in the opinion of the investigator, precludes trial participation. This includes any acute, subacute, intermittent, or chronic medical disease or condition that would place the Participant at an unacceptable risk of injury, render the Participant unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the Participant's successful completion of the trial; (Chronic conditions that are well-controlled and medically stable, i.e. no relevant change in treatment for medical reasons occurred in the last 6 months, are allowed at the discretion of the PI, e.g. hypertension, asthma, thyroid disease) Any confirmed or suspected or immunodeficient condition resulting from disease (e.g., , [HIV] infection) or immunosuppressive/cytotoxic therapy (e.g., medications used during cancer chemotherapy, organ transplantation or to treat disorders) and any infection requiring IV antibiotics or hospitalization within 90 days prior to screening
  3. History of Guillain-Barré syndrome
  4. History of allergy to any component of the vaccine
  5. Serology screen positive for infectious diseases (, , HIV, Human T-cell leukemia virus (HTLV), Syphilis);
  6. Known prior exposure to Marburg virus or prior diagnosis of Marburg Virus Disease, determined from the participant's reported medical history
  7. History of or active status of any of the following conditions:

    1. Serious adverse reactions to vaccines such as anaphylaxis, urticaria (hives), respiratory difficulty, angioedema, or abdominal pain;
    2. Allergic reaction to in the trial vaccine including gentamycin, neomycin or streptomycin;
    3. Diabetes mellitus Type I or Type II (even if stable)
    4. Tuberculosis
    5. Hereditary angioedema (HAE), acquired angioedema (AAE), or idiopathic forms of angioedema;
    6. Idiopathic urticaria within the last year
    7. Any malignancy, including non-skin melanoma, that has been active or treated, within 5 years prior to screening. (If diagnosed malignancy is 5 or more years prior to enrollment and cured with no ongoing treatment the malignancy will NOT be considered an exclusion);
    8. Seizure in the past 3 years or treatment for seizure disorder in the past 3 years (even if stable);
    9. Asplenia or functional asplenia;
    10. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a to protocol participation or impairs a participant's ability to give ;
  8. Hematologic History:

    1. Bleeding disorder diagnosed by a doctor or use of anticoagulant medications such as, Warfarin, Apixaban, Dabigatran (e.g. factor deficiency, coagulopathy, or disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws;
    2. Family and personal history of bleeding or thrombosis or heparin-induced thrombocytopenia
    3. Conditions known to increase risk of thrombosis (e.g., pregnant or post-partum, extreme obesity, active malignancy or post-transplantation, recent surgery, immobility, recent infection, recent head trauma, autoimmune disease, inflammatory disease),
    4. Receipt of blood products within 3 months prior to enrollment.
    5. Has donated ≥ 450 mL of blood products within 30 days prior to randomization or expects to donate blood within 90 days of vaccine administration
    6. History of heparin-related thrombotic events, and/or receiving heparin treatments
  9. Has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature ≥38.0° Celsius (≥100.4° Fahrenheit) within 24 hours of the planned dose of trial vaccine, rescreening and randomization at a later date is permitted at the discretion of the investigator and after consultation with the sponsor
  10. Receipt of any of the following substances:

    1. prior receipt of Sudan Virus Vaccine or Marburg Vaccine
    2. prior receipt of any adenoviral vectored vaccine, adenovirus-based or adeno-associated virus (AAV)-based gene therapies or treatments, including adenoviral COVID-19 vaccines or boosters.
    3. Participant received an drug (including investigational drugs for prophylaxis of COVID-19) within 3 months of dosing, or has used an invasive investigational medical device within 3 months of dosing
    4. received immunoglobulin (Ig) or monoclonal antibodies within 3 months,
    5. is currently enrolled or plans to participate in another investigational or interventional trial during the course of this trial (observational/registry trials are allowed)
  11. Use of systemic in daily dose equivalence > 20 mg of prednisolone in the last 90 days, and for periods exceeding 10 days. Non-steroidal anti-inflammatory drugs [NSAIDS] are permitted.
  12. Current anti-tuberculosis prophylaxis or therapy
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    cAd3-Marburg Vaccine (1.0 × 10^11 PU)

    Single dose of cAd3-Marburg Vaccine (1x10\^11 PU) administered intramuscularly (IM) with needle and syringe in a volume of 0.71 mL.

    Biological: cAd3-Marburg Vaccine

  • Placebo comparator
    Placebo 0.9% NaCl solution

    Single dose of Placebo (0.9% NaCl solution for injection) administered intramuscularly (IM) with needle and syringe in a volume of 0.71 mL.

    Biological: Placebo

Interventions

  • BiologicalcAd3-Marburg Vaccine

    The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, (cAd3-Marburg Vaccine) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP) from the Angola strain.

  • BiologicalPlacebo

    0.9% NaCl solution for injection.

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of cAd3-Marburg Vaccine, by count and percentage of vaccinated participants who develop: SAEs, solicited/unsolicited AEs, AESI, MAAE, and AE at each intensity level of cAd3-Marburg Vaccine

    Count and percentage of vaccinated participants who develop: serious adverse events (SAEs), solicited adverse events (AEs), unsolicited AEs, adverse event of special interest (AESI), medically attended adverse events (MAAE), and AE at each intensity level. Estimand 1a (Primary): Count and percentage of vaccinated participants who would develop SAEs, solicited AEs, unsolicited AEs, AESI, MAAE, and AE at each intensity level will be evaluated with each treatment group. A treatment policy strategy is used for assessing safety irrespective of a current (or prior) infection at time of the vaccination. Infections and death (if vaccinated participants meet the AE and time window criteria) are included in the endpoint (composite strategy).

    Time frame: 1 Year

Secondary outcomes

  1. To determine the geometric mean concentration (GMC) of anti-Marburg-GP binding IgG antibodies to cAd3-Marburg Vaccine at Day 29 post-vaccination.

    Secondary Endpoint: To evaluate the humoral immunogenicity induced by cAd3-Marburg Vaccine at Day 29 post-vaccination. Estimand 2a: Geometric mean concentration (GMC) of cAd3-Marburg Vaccine will be compared to placebo on Day 29 post-vaccination. The hypothetical strategy is used to estimate antibody levels without subsequent Marburg virus (MARV) infection or influence from immune-modifying drugs or non-trial interventions. The principal stratum strategy excludes those with active or prior MARV infection at the time of the vaccination.

    Time frame: 29 Days

  2. To determine geometric mean increase (GMI) of anti-Marburg-GP binding IgG antibodies at Day 29 post-vaccination

    Secondary Endpoint: To evaluate the humoral immunogenicity induced by cAd3-Marburg Vaccine at Day 29 post-vaccination. Estimand 2b: Geometric mean increase (GMI) of anti-Marburg-GP binding IgG antibodies against Marburg-GP on Day 29. The hypothetical strategy is used to estimate antibody levels without subsequent Marburg virus (MARV) infection or influence from immune-modifying drugs or non-trial interventions. The principal stratum strategy excludes those with active or prior MARV infection at the time of the vaccination.

    Time frame: 29 Days

  3. To determine the geometric mean of the ND50 (GMND50) of anti-Marburg-GP neutralizing antibodies on Day 29 post-vaccination.

    Secondary Endpoint: To evaluate the humoral immunogenicity induced by cAd3-Marburg Vaccine at Day 29 post-vaccination. Estimand 2c: The geometric mean of the ND50 (GMND50) of anti-Marburg-GP neutralizing antibodies on Day 29. The hypothetical strategy is used to estimate antibody levels without subsequent Marburg virus (MARV) infection or influence from immune-modifying drugs or non-trial interventions. The principal stratum strategy excludes those with active or prior MARV infection at the time of the vaccination.

    Time frame: 29 Days

  4. To determine the geometric mean increase of the ND50 (GMIND50) of anti-Marburg-GP neutralizing antibodies at Day 29 post-vaccination.

    Secondary Endpoint: To evaluate the humoral immunogenicity induced by cAd3-Marburg Vaccine at Day 29 post-vaccination. Estimand 2d: The geometric mean increase of the ND50 (GMND50) of anti-Marburg-GP neutralizing antibodies on Day 29. The hypothetical strategy is used to estimate antibody levels without subsequent Marburg virus (MARV) infection or influence from immune-modifying drugs or non-trial interventions. The principal stratum strategy excludes those with active or prior MARV infection at the time of the vaccination.

    Time frame: 29 Days

  5. To determine the percentage of participants (and 95%CI) with seroconversion at Day 29 post-vaccination.

    Secondary Endpoint: To evaluate the humoral immunogenicity induced by cAd3-Marburg Vaccine at Day 29 post-vaccination. Estimand 2e: Percentage of participants (and 95%CI) with seroconversion at Day 29. The hypothetical strategy is used to estimate antibody levels without subsequent Marburg virus (MARV) infection or influence from immune-modifying drugs or non-trial interventions. The principal stratum strategy excludes those with active or prior MARV infection at the time of the vaccination.

    Time frame: 29 Days

  6. To determine the geometric mean concentration (GMC) of anti-Marburg-GP binding IgG antibodies on Day 1, Day 8, Day 15, Day 85, Day 169, and Day 366.

    Secondary Endpoint: To evaluate the humoral immunogenicity induced by cAd3-Marburg Vaccine across additional trial timepoints. Estimand 3a: GMCs of anti-Marburg-GP binding IgG antibodies on Day 1, Day 8, Day 15, Day 85, Day 169, and Day 366. The hypothetical strategy is used to estimate antibody levels without subsequent Marburg virus (MARV) infection or influence from immune-modifying drugs or non-trial interventions. The principal stratum strategy excludes those with active or prior MARV infection at the time of the trial intervention.

    Time frame: 1 Year

  7. To determine the geometric mean increase (GMI) of anti-Marburg-GP binding IgG antibodies against Marburg-GP at optional selected timepoints (Day 8, Day 15, Day 85, Day 169, and Day 366).

    Secondary Endpoint: To evaluate the humoral immunogenicity induced by cAd3-Marburg Vaccine across additional trial timepoints. Estimand 3b: GMI of anti-Marburg-GP binding IgG antibodies against Marburg-GP at optional selected timepoints (Day 8, Day 15, Day 85, Day 169, and Day 366). The hypothetical strategy is used to estimate antibody levels without subsequent Marburg virus (MARV) infection or influence from immune-modifying drugs or non-trial intervention. The principal stratum strategy excludes those with active or prior MARV infection at the time of the trial intervention.

    Time frame: 1 Year

  8. To determine geometric mean increase of the ND50 (GMIND50) of anti-Marburg-GP neutralizing antibodies on Day 1, Day 8, Day 15, Day 85, Day 169, and Day 366.

    Secondary Endpoint: To evaluate the humoral immunogenicity induced by cAd3-Marburg Vaccine across additional trial timepoints. Estimand 3c: GMIND50 of anti-Marburg-GP neutralizing antibodies on Day 1, Day 8, Day 15, Day 85, Day 169, and Day 366. The hypothetical strategy is used to estimate antibody levels without subsequent Marburg virus (MARV) infection or influence from immune-modifying drugs or non-trial interventions. The principal stratum strategy excludes those with active or prior MARV infection at the time of the trial intervention.

    Time frame: 1 Year

  9. To determine geometric mean increase of ND50 of anti-Marburg-GP neutralizing antibodies at optionally selected timepoints (Day 8, Day 15, Day 85, Day 169, and Day 366)

    Secondary Endpoint: To evaluate the humoral immunogenicity induced by cAd3-Marburg Vaccine across additional trial timepoints. Estimand 3d: GMIND50 of anti-Marburg-GP neutralizing antibodies at optionally selected timepoints (Day 8, Day 15, Day 85, Day 169, and Day 366). The hypothetical strategy is used to estimate antibody levels without subsequent Marburg virus (MARV) infection or influence from immune-modifying drugs or non-trial interventions. The principal stratum strategy excludes those with active or prior MARV infection at the time of the trial intervention.

    Time frame: 1 Year

  10. To determine the percentage of participants (and 95%CI) with seroconversion at Day 8, Day 15, Day 85, Day 169, and Day 366.

    Secondary Endpoint: To evaluate the humoral immunogenicity induced by cAd3-Marburg Vaccine across additional trial timepoints. Estimand 3e: Percentage of Participants (and 95%CI) with seroconversion at Day 8, Day 15, Day 85, Day 169, and Day 366. The hypothetical strategy is used to estimate antibody levels without subsequent Marburg virus (MARV) infection or influence from immune-modifying drugs or non-trial interventions. The principal stratum strategy excludes those with active or prior MARV infection at the time of the trial intervention.

    Time frame: 1 Year

Other outcomes

  1. To determine cell-mediated immune response to cAd3-Marburg Vaccine at Day 1, Day 15, Day 29, Day 169, and Day 366 in a subset of 40 Participants

    Exploratory Objective: If deemed necessary, to further characterize the immune response of cAd3-Marburg Vaccine. Estimand 4a: Frequency of IFN-γ secreting T-cells by ELISpot. Percentage of CD4+ T-cells and/or CD8+ T-cells that producing IFN-γ and/or IL-2 and/or TNF-α, as measured by ICS.

    Time frame: 1 Year

  2. To determine the geometric mean concentration (GMC) of anti-Marburg-GP binding IgM antibodies at Day 1, Day 8, Day 15, and Day 29.

    Exploratory Objective: If deemed necessary, to further characterize the immune response of cAd3-Marburg Vaccine. Further exploratory immunology to detect cAd3-Marburg Vaccine-related immune responses. Estimand 4b: The GMC of anti-Marburg-GP binding IgM antibodies at Day 1, Day 8, Day 15, and Day 29.

    Time frame: 29 Days

  3. To determine Systems serology (multiple assays in high throughout screen) D1 and D29

    Exploratory Objective: If deemed necessary, to further characterize the immune response of cAd3-Marburg Vaccine. Further exploratory immunology to detect cAd3-Marburg Vaccine-related immune responses. Estimand 4c: Systems serology (multiple assays in high throughout screen) D1 and D29

    Time frame: 29 Days

07

Study locations

7 sites
  • Optimal Research; LLC
    Huntsville, Alabama 35802, United States
  • Synexus Clinical Research US, Inc.
    Phoenix, Arizona 85020, United States
  • Optimal Research; LLC
    Melbourne, Florida 32934, United States
  • Synexus Clinical Research US, Inc.
    Chicago, Illinois 60602, United States
  • Optimal Research; LLC
    Peoria, Illinois 61614, United States
  • Synexus Clinical Research US; Inc.
    Dallas, Texas 75234, United States
  • Synexus Clinical Research US, Inc.
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: Yes — The clinical trial results will be published in a peer-reviewed journal, which will include, as feasible, the study protocol. A summary of the study results will be included within the trial registration records in ClinicalTrials.gov.

Time frame: The sponsor will also publish results in a manuscript in a peer reviewed journal, which requires a published study protocol. The sponsor expects this will be done by early 2027.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Oct 2026, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2024
First posted
Oct 1, 2024
StartActual
Apr 14, 2025
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06620003
Lead sponsor
Albert B. Sabin Vaccine Institute
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Oct 1, 2024
Start date
Apr 14, 2025
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Sep 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion